Overcoming target heterogeneity in gastric cancer with an eKiH-engineered CLDN18.2×HER2 bispecific ADC (AACR 2026) - Mar 18, 2026 - Abstract #1728/25; Pres time: Apr 20, 2026; 09:00 AM - 12:00 PM; Location: Section 13; "We previously developed DA3501 (AT-211), a CLDN18.2-targeting ADC currently advancing toward Phase 1 evaluation. The DA3501 antibody clone demonstrates enhanced affinity and internalization compared with zolbetuximab... This BsAb is a rationally engineered CLDN18.2×HER2 bispecific ADC designed to overcome target heterogeneity in GC. Together with the DA3501 program, it broadens therapeutic coverage of CLDN18.2/HER2-expressing tumors and combination-strategy studies, including ICI co-therapy."
ADC • Bispecific • Heterogeneity • IO biomarker • Gastric Cancer • Oncology • Solid Tumor • CLDN18 • HER-2
|
|
Kyoung-Ho Pyo1; Seong-Hyun Park1; Dongsop Lee2; Haneol Kim2; Younggyu Kong2; Younggeun Lee1; Hojin Yeom1; Sowon Aum1; Sun Hee Park1; Huijo Oh1; Cheyeon Kim1; Hyeonseok Jin2; Aera Lee2; Hojeong Hong2; Ju Hwan Kim1; Hyungseok Choi2; Mi-Kyung Kim2; Taedong Han1
|